SCHEMBL3080048

SCHEMBL3080048

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2cccc(OC)c2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.54
KMT2A Q03164 7/20 0.54
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
KAT6A Q92794 2/20 0.52
MAPT P10636 5/20 0.49
LMNA P02545 3/20 0.49
KCNA5 P22460 1/20 0.47
POLB P06746 3/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 1/20 0.47
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.46
RECQL P46063 1/20 0.46
PLAU P00749 1/20 0.46
MMP2 P08253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3100199 0.92 NPC1 (0.53) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3093901 0.91 MMP9 (0.46) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3102970 0.91 MMP9 (0.46) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3092720 0.90 MEN1 (0.53) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3093289 0.89 KAT6A (0.49) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3085893 0.89 NPC1 (0.52) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3096373 0.89 NPC1 (0.52) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3097645 0.89 KAT6A (0.49) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3103861 0.89 KAT6A (0.52) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3088121 0.88 ALOX15 (0.43) MEN1KMT2ANPC1RAB9AKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MEN1 2509/4885KMT2A 1948/4885NPC1 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.